[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitamin-d\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitamin-d":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,50,77,103,130,160,186,221,252,278],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100616032","exercise-training-and-vitamin-d-metabolism-100616032",false,"NCT07300332","Exercise Training and Vitamin D Metabolism","The Impact of Hybrid-type High-intensity Interval Training on Vitamin D Metabolism in Adults With Overweight\u002FObesity","Hybri-D","Inclusion Criteria:\n\n* BMI = 25-35 kg\u002Fm2\n* Absence of musculoskeletal injuries\n* Absence of chronic health-related complications\n* Non-smokers\n\nExclusion Criteria:\n\n* Consumption of Vitamin D supplements\n* Consumption of anti-inflammatory drugs, statins and\u002For steroids",true,"ALL","35 Years","50 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"NA","The prevalence of Vitamin D deficiency is significantly higher in adults with overweight\u002Fobesity compared to those with normal body mass index (BMI). The \"entrapment\" of Vitamin D in adipose tissue due to impaired lipolytic stimulation and\u002For adipose tissue dysfunction has been proposed as the driving mechanism. Exercise training has been proposed as a promising strategy to increase mobilization of Vitamin D from adipose tissue, given its well described role in stimulating lipolysis. Indeed, a recent study revealed that participation in moderate-intensity cardiovascular type exercise over winter can mitigate the decline in 25-hydroxyvitamin D \\[25(OH)D\\] in adults with overweight\u002Fobesity, independent of weight loss. The aim of this study is to investigate the impact of hybrid-type high-intensity interval training over winter on vitamin D metabolism, in adults with overweight\u002Fobesity.",[29,30],"Obesity & Overweight","Vitamin D",[32,33,34,35,36],"overweight","obesity","vitamin D","25-hydroxyvitamin D","high-intensity interval training","RECRUITING","2026-05-22",{"date":40,"type":41},"2026-05-26","ACTUAL",{"date":43,"type":41},"2025-11-10",{"date":45,"type":23},"2026-07-20",{"name":47,"class":48},"University of Thessaly","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":17,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100636517","pilates-vs-aerobic-exercises-on-vitamin-d-and-ionized-calcium-in-postnatal-100636517","NCT07566715","Pilates vs Aerobic Exercises on Vitamin D and Ionized Calcium in Postnatal","Effect of Pilates Versus Aerobic Exercises on Vitamin D Level and Ionized Calcium in Postnatal Women","Inclusion Criteria:\n\n1. Their ages were ranged from 18-40 years old.\n2. Their body mass index (BMI) was ranged from 25-35 kg\u002F m².\n3. They were postnatal period by 6-12 weeks.\n4. They were primipara or multipara.\n5. They were healthy postpartum women.\n\nExclusion Criteria:\n\n1. High risk pregnant history.\n2. Sever postpartum complications.\n3. Cardiovascular diseases i.e., utilizing pace maker.\n4. Skeletal deformity.\n5. Participation at any other exercise training program during this study.\n6. Malignant conditions.\n7. History of acute infection\n8. Neurological problem; epileptic fits…etc.\n9. Mental problem to prevent evaluation and cooperation.\n10. Renal, liver or endocrinal disorders.\n11. Pulmonary disorders.","FEMALE","18 Years","40 Years",{"count":61,"type":23},60,[26],"Vitamin D and calcium levels are negatively affected during postpartum period, making postnatal woman more vulnerable to health issues and consequently lowering her quality of life. Twelve-weeks of Pilates training have improved serum 25-hydroxy vitamin D levels and changed anthropometry in inactive overweight women. It is well-known globally that aerobic exercise is low to moderate-intensity physical activity.",[65,30],"Postnatal Women","NOT_YET_RECRUITING","2026-04-30",{"date":69,"type":41},"2026-05-05",{"date":71,"type":23},"2026-05-01",{"date":73,"type":23},"2026-12-30",{"name":75,"class":48},"Adly A Adam",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":58,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":87,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100602767","non-inferiority-rct-on-fish-waste-derived-vs-synthetic-vitamin-d-supplementation-in-healthy-adults-with-suboptimal-vitamin-d-levels-100602767","NCT07127796","Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vitamin D Levels","A Non-inferiority, Randomized Double-blind Controlled Clinical Trial Comparing the Effect of Vitamin D Supplementation Derived From Fish Waste Versus Synthetic Vitamin D on Plasma Vitamin D Levels and Anthropometric and Laboratory Correlates in Healthy Subjects With Suboptimal Blood Vitamin D Levels","Inclusion Criteria:\n\n* Male or female aged ≥ 18 years and ≤ 60 years old\n* Vitamin D plasma level between 20 and 40 ng\u002FmL\n* Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements\n* Subjects agree to participate in the study and having dated and signed the informed consent form\n\nExclusion Criteria:\n\n* Intake of dietary supplements or drugs containing Vitamin D\n* Diagnosis of osteopenia\u002Fosteoporosis, rheumatological diseases, history of non-traumatic bone fractures\n* Known diagnosis of hyperparathyroidism, hypercalcemia, severe renal failure (eGFR\\\u003C30 mg\u002FdL) Known intolerance or allergy to fish or fish derived products\n* Any preventive treatments (i.e. hypocholesterolemics, antihypertensives) not stabilized in type and dose for at least 3 months\n* Active pregnancy or lactation\n* Any medical or surgical condition that would limit the patient adhesion to the study protocol","60 Years",{"count":86,"type":23},48,[26],"Vitamin D is a fat-soluble vitamin with hormone-like properties, essential for numerous physiological processes in humans. It plays a central role in maintaining calcium and phosphorus homeostasis, promoting intestinal absorption of these minerals, and ensuring optimal bone mineralization. There are two main forms: vitamin D2 (ergocalciferol), primarily obtained from plant sources and supplements, and vitamin D3 (cholecalciferol), synthesized endogenously in the skin through exposure to ultraviolet B (UVB) radiation and present in animal-derived foods such as fatty fish, liver, and egg yolks. Beyond its well-known skeletal functions, vitamin D contributes to muscle contraction, immune system modulation, and regulation of cell proliferation and differentiation. Increasing evidence suggests that adequate vitamin D status may benefit cardiovascular health, glucose metabolism, and possibly reduce the risk of certain cancers, while supplementation has been associated with improved plasma lipid profiles, a relevant factor in cardiovascular risk reduction. The European Food Safety Authority has authorized various health claims for vitamin D, including its role in normal calcium and phosphorus absorption and utilization, maintenance of normal blood calcium concentrations, bone and teeth health, normal muscle function, immune defense, and reduction of the risk of falls in older adults. Despite its importance, vitamin D deficiency is recognized as a widespread public health concern across Europe, with prevalence influenced by latitude, season, skin pigmentation, and lifestyle habits. Data indicate that up to 40% of Europeans have suboptimal vitamin D levels, with deficiency rates exceeding 70% in specific high-risk groups such as elderly individuals, people with dark skin, and those with limited sun exposure. In Italy, despite abundant sunlight, vitamin D insufficiency is highly prevalent, particularly in older adults and patients with chronic illnesses. Contributing factors include urbanization, sedentary lifestyles, reduced time spent outdoors, and cultural or clothing practices limiting sun exposure. Approximately half of the Italian population is estimated to have insufficient vitamin D levels, with rates rising in the northern regions during winter months. Prolonged deficiency has severe consequences for skeletal health, including rickets in children, osteomalacia in adults, and increased risk of osteoporosis and fractures. It is also linked to a broad range of extra-skeletal effects, such as impaired immune response with greater susceptibility to infections, increased risk of chronic diseases including cardiovascular disorders, type 2 diabetes, and certain cancers, as well as muscle weakness, higher likelihood of falls, and mood disorders such as depression and seasonal affective disorder. Addressing vitamin D deficiency requires a multifaceted approach involving dietary supplementation, food fortification strategies, and public health initiatives promoting safe sunlight exposure. Severe deficiency requires pharmacological treatment with appropriately dosed medications, whereas mild deficiency can be corrected through over-the-counter supplements. In Italy, vitamin D supplements contain up to 2000 IU per day, with the recommended daily allowance for healthy adults set at 600 IU. The demand for vitamin D supplementation is reflected in market trends: the global market was valued at USD 1.69 billion in 2022 and is projected to reach USD 3.44 billion by 2031, with an estimated compound annual growth rate of 8.22% between 2023 and 2031. Against this background, the exploration of natural, sustainable sources of vitamin D, particularly from food industry by-products such as fish waste, offers an environmentally friendly alternative to synthetic forms currently dominating the market. This concept underpins the PRIN research project \"Innovative and sustainable processes for the development of Vitamin D nutraceutical from fish waste: extraction, formulation and clinical study for the evaluation of its bioavailability and clinical consequence\" (VITADWASTE; 2022M9JL3%; National Coordinator: Prof. Gianni Sagratini, University of Camerino), supported by the Italian Ministry of University. The project aims to develop and clinically evaluate a fish-derived vitamin D nutraceutical as a sustainable solution. Within this context, the primary objective of the present randomized, double-blind, non-inferiority clinical trial is to assess whether supplementation with fish-derived vitamin D at a dose of 600 IU per day, corresponding to 100% of the recommended daily intake for healthy adults, has an effect on plasma vitamin D levels comparable to that of an equivalent dose of standard synthetic vitamin D in healthy adults with mild vitamin D deficiency, defined by plasma concentrations between 20 and 40 ng\u002FmL.",[30,90],"Dietary Supplement",[30,92,93,94],"Dietary supplement","Food waist","Fish-derived vitamin D","2026-04-27",{"date":71,"type":41},{"date":98,"type":23},"2026-09-01",{"date":100,"type":23},"2027-09-10",{"name":102,"class":48},"University of Bologna",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":57,"minAge":110,"maxAge":59,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":76},"100473705","vitamin-d-epigallocatechin-gallate-d-chiro-inositol-and-vitamin-b6-in-uterine-fibroid-100473705","NCT05448365","Vitamin D, Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in Uterine Fibroid","The Use of Vitamin D in Combination With Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in the Treatment of Women With Uterine Fibroid","Inclusion Criteria:\n\n1. uterine fibroid with diameter greater than or equal to 4cm or multiple fibroids\n2. eligible for surgery\n3. symptoms like menometrorrhagia or pelvic pain\n\nExclusion Criteria:\n\n1. BMI\\>30\n2. currently pregnant or breastfeeding\n3. diabetic\n4. suspect of malignancy\n5. diagnosis of cancer","30 Years",{"count":61,"type":23},[26],"The study will evaluate the impact on uterine fibroids' volume of a combination of natural molecules including Epigallocatechin gallate, Vitamin D, D-chiro-inositol and Vitamin B6.\n\nThe patients will be evaluated at baseline and after three months of treatment with placebo or product.",[115,116,117,118,30,119],"Uterine Fibroids","D-chiro-inositol","Inositol","Epigallocatechin Gallate","Vitamin B6","2026-02-10",{"date":122,"type":41},"2026-02-12",{"date":124,"type":41},"2022-07-01",{"date":126,"type":23},"2026-07-01",{"name":128,"class":129},"Lo.Li.Pharma s.r.l","INDUSTRY",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":57,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":141,"briefSummary":143,"conditions":144,"keywords":147,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":49},"100615145","phase-4-vitamin-d-for-preventing-recurrent-preeclampsia-in-pregnant-women-100615145","NCT07288801","Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women","Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia\n\nExclusion Criteria:\n\n* Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record)\n* Women presenting with intra-uterine death of the fetus.","20 Years","45 Years",{"count":140,"type":23},146,[142],"PHASE4","The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is:\n\nDoes vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia?\n\nTo answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study.\n\nParticipants will be randomly assigned to two equal groups:\n\n* Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation.\n* Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D.\n\nWhile on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140\u002F90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded.\n\nAt the end, researchers will compare how many women in each group developed recurrent pre-eclampsia.\n\nThis study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.",[145,146,30],"Pre-eclampsia","Pregnancy",[148,149,150,30],"pre-eclampsia","pregnancy","recurrence","2025-12-04",{"date":153,"type":41},"2025-12-17",{"date":155,"type":41},"2025-08-09",{"date":157,"type":23},"2026-02-08",{"name":159,"class":48},"Nishtar Medical University",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":17,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":170,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":49},"100613603","free-vitamin-d-and-steroid-metabolism-in-endocrine-disorders-100613603","NCT07268742","Free Vitamin D and Steroid Metabolism in Endocrine Disorders","Free Fraction Vitamin D Measurements to Improve Understanding of Steroid Metabolism in Endocrine Disorders","FREEDOM","1. General inclusion Criteria:\n\n   \\- 18 years or above\n2. General exclusion Criteria:\n\n   * Below 18 years of age\n   * Individuals incapable of providing informed consent\n3. Cohort inclusion criteria\n\n   * Obesity: BMI ≥ 25 kg\u002Fm2\n   * Chronic Kidney Disease: ≥ CKD stage 3a (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73m2)\n   * Pregnancy: in trimester 1 of pregnancy\n   * Primary hyperparathyroidism: diagnosis at UZ Leuven and scheduled for parathyroidectomy at UZ Leuven\n   * Complex calcium and phosphate disorders: diagnosis at UZ Leuven\n4. Cohort exclusion criteria\n\n   * Healthy controls: BMI below 18 kg\u002Fm² or above 25 kg\u002Fm², pregnancy, chronic kidney disease (independent of staging), primary hyperparathyroidism and vitamin D and\u002For calcium supplementation\n   * Obesity: chronic kidney disease (independent of staging), pregnancy, primary hyperparathyroidism\n   * Chronic Kidney Disease: BMI below 18 kg\u002Fm² or above 30 kg\u002Fm², pregnancy, primary hyperparathyroidism\n   * Pregnancy: BMI below 18 kg\u002Fm² or above 30 kg\u002Fm², chronic kidney disease (independent of staging), primary hyperparathyroidism\n   * Primary hyperparathyroidism: BMI below 18 kg\u002Fm² or above 30 kg\u002Fm², pregnancy, chronic kidney disease (independent of staging), secondary hyperparathyroidism",{"count":169,"type":23},930,"OBSERVATIONAL","This clinical study aims to gain a better understanding of how different forms of vitamin D are processed in the body in healthy individuals, pregnant women, and patients with various hormonal (endocrine) and kidney (renal) disorders. In the long term, this study may provide new insights that could how vitamin D is tested and interpreted in these groups.\n\nVitamin D has several important roles in the body, such as building strong bones and maintaining calcium balance in the blood. Most vitamin D in the blood circulation is attached\u002Fbound to a protein called \"vitamin D binding protein\" (VDBP), which makes it unavailable for the body to use. A much smaller portion circulates freely in the blood and this is called \"free vitamin D\". This free form can be directly used by the body.\n\nWhen your doctor tests your vitamin D levels, this usually refers to total vitamin D (the sum of bound and free vitamin D). However, this total value may not give an accurate indication of your actual vitamin D status, since most of it (the bound part) cannot be used by the body. The purpose of this study is to examine whether \"free vitamin D\" is a better marker of vitamin D status and if the amount of free vitamin D differs between healthy people, pregnant women, and people with specific endocrine or kidney disorders.\n\nAdditionally, this study will look into vitamin D metabolism more detailed, and investigate what different forms of vitamin D exist, how the body processes these, and whether these forms may be related to certain endocrine or kidney conditions.",[30,173],"Vitamin D and Calcium Homeostasis",[30,175,176],"Free vitamin D","Free hormone hypothesis","2025-12-03",{"date":179,"type":41},"2025-12-08",{"date":181,"type":41},"2024-06-01",{"date":183,"type":23},"2029-10",{"name":185,"class":48},"Universitaire Ziekenhuizen KU Leuven",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":18,"minAge":58,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":197,"briefSummary":198,"conditions":199,"keywords":205,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":49},"100604729","assessing-bone-fracture-healing-effect-of-almonds-100604729","NCT07153302","Assessing Bone Fracture Healing Effect of Almonds","Assessing Bone Fracture Healing Effect of Prunus Dulcis (Almonds) - A Randomized Controlled Trial","AFHEA","Inclusion Criteria:\n\n1. Patients of 18 to 55 years of age of any gender.\n2. Agree and able to voluntary participate.\n3. Patients with trauma associated femur fracture and tibia shaft fracture arriving at hospital for treatment.\n\nExclusion Criteria:\n\n1. Mentally retarded or patients with severe psychiatric illness.\n2. Patients are already on bone-strengthening drugs (bisphosphonates, vitamin D, strontium ranelate, teriparatide, etc.).\n3. Patients who require bone-strengthening drugs for osteoporosis or for any urgent need.\n4. Severe cardiovascular, hepatic, or renal disease.\n5. Known allergy or toxicity to Prunus dulcis (almonds) and\u002For vitamin D supplements.","55 Years",{"count":196,"type":23},136,[26],"Femur and tibia shaft fractures are common after trauma with a burden of 5% and 20% respectively. Clinicians recommend costly bone strengthening drugs\u002Fsupplements while treating bone fractures. These drugs have side effects and are costly due to which patients skip these supplements. Routinely prescribed vitamin D have known toxicity. To overcome this problem, affordable and safe alternative treatment is needed. Sweet almonds contain essential bone nutrients that might have potential for maintaining bone strength. Human and animal studies have shown positive impact of almonds on bone health and fracture healing. Almonds are consumed in diet frequently but may occasionally cause toxicity, mainly if consumed at higher amount. Because of the high bone essential nutrients in almonds, the trial aimed to investigate the fracture healing effect and safety of almonds in femur and tibia shaft fractures. This might provide an alternate option for bone supplants while treating fractures.\n\nHypothesis: Compared to routine vitamin D3, almonds non-inferiorly improves fracture callus index and raise vitamin D3 level in blood in femur and tibia shaft fracture patients.\n\nPrimary Objectives:\n\n1. To compare tibia and femur shaft fracture callus index and callus bridging on x-rays at 4 and 13 weeks herewith group 1 suffering vitamin D insufficiency (arm A versus arm B) and group 2 suffering vitamin D deficiency (arm B versus arm C) treated as cross-over with oral whole almonds and vitamin D3.\n2. To compare the incidence of adverse events between almonds and vitamin D3 treatments up to 13 weeks follow-up.\n\nSecondary Objectives:\n\n1. To compare the almonds and vitamin D3 treatment cost.\n2. To compare within group blood vitamin D levels (ng\u002FmL) at baseline and post-treatment follow-ups.\n\nMethods:\n\nStudy design: Single-center, open-labeled, crossover, non-inferiority randomized controlled trial.\n\nTotal 136 subjects are required with 14 subjects in group 1 and 122 in group 2.in 24-month duration.\n\nStudy procedures:\n\n1. Regulatory and Ethical approvals.\n2. Patient screening and eligibility assessment. Patients, of 18 to 55 years of age of any gender, with trauma associated femur and tibia shaft fractures who agree to voluntary participate are included and mentally retarded or patients with severe psychiatric illness, already on or require bone-strengthening drugs , having severe cardiovascular, hepatic, or renal disease, known allergy\u002Ftoxicity to almonds and\u002For vitamin D supplements.\n3. Written informed consent administration.\n4. Randomization Patients (N=136) are divided into two groups. Group 1 (N=14, vitamin D insufficiency, blood vitamin D level 21-29 ng\u002FmL) and Group 2 (N=122, vitamin D deficiency, blood vitamin D level ≤20 ng\u002FmL).\n\n   I. Group 1 (N=14):\n\n   Arm A (n=7)=5 grams\u002Fday of almonds for 4 weeks, followed by 7 days washout period and cross-over treatment by oral vitamin D3 200,000 units\u002Fweek for 8 weeks.\n\n   Arm B (n=7)=Oral vitamin D3 200,000 units\u002Fweek for 8 weeks, followed by 7 days washout period and cross-over treatment by 5 grams\u002Fday of almonds for 4 weeks\n\n   II. Group 2 (N=122):\n\n   Arm B (n=61)=Oral vitamin D3 200,000 units\u002Fweek for 8 weeks, followed by 7 days washout period and cross-over treatment by 5 grams\u002Fday of almonds for 4 weeks.\n\n   Arm C (n=61)=Oral vitamin D3 200,000 units\u002Fweek together with 5 grams\u002Fday almonds for 4 weeks, followed by 7 days washout period and cross-over treatment by oral vitamin D3 200,000 units\u002Fweek for 8 weeks.\n5. Patients are followed at 4 weeks and 13 weeks follow-ups after treatment.\n6. Fracture site routine X-rays and RUST scores are assessed by treating surgeon\u002Finvestigator(s) at follow-ups for bone fracture healing.\n7. Investigational product (IP) safety assessment and reporting as per ICH-GCP guidelines. Subjects experiencing any adverse event (AE)\u002Fserious adverse event (SAE) is provided optimum care at earliest. All relevant reporting bodies are notified within recommended timeline.\n8. The almonds are regularly purchased from the Purchase Department of the Hospital, weighted, packaged and labelled, and stored at the secure dry hygienic place. The product is dispensed to the patient and a daily IP diary is provided for compliance.\n9. Patients can withdraw from the study at any time without losing any of his\u002Fher patient rights.\n10. Study close-out process will be of one to two-month duration.\n\nStatistical analysis:\n\nThe SPSS version 19.0 will be used to analyze data. Quantitative variables will be expressed as mean±SD\u002Fmedian (IQR) and qualitative as frequencies (%). IP related AEs\u002FSAEs will be assessed by incidence\u002Fstratification. Witin group and within arm comparisons for the radiological assessments and vitamin D3 level will be analyzed by ANOVA and GEE. Within arm tibia and femur fracture outcomes will be compared by independent t-test\u002FMann Whitney U test. The p-value \\\u003C0.05 is considered significant. Multiple regression analysis for association of covariates and outcome will be used.",[200,201,30,202,203,204],"Femur Shaft Fracture","Tibia Fractures","Sweet Almonds","Callus Index","Callus Bridging",[206,207,208,209,210,211],"callus bridging","callus index","femur shaft fracture","tibia shaft fracture","Prunus dulcis (almonds)","vitamin D3","2025-08-30",{"date":214,"type":41},"2025-09-03",{"date":216,"type":41},"2024-08-20",{"date":218,"type":23},"2026-07",{"name":220,"class":48},"Aga Khan University Hospital, Pakistan",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":18,"minAge":229,"maxAge":58,"enrollmentInfo":230,"targetDuration":4,"studyType":24,"phases":232,"briefSummary":233,"conditions":234,"keywords":237,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":49},"100581212","efficacy-and-safety-of-vitamin-d-supplementation-in-pediatric-patients-with-obesity-100581212","NCT06847373","Efficacy and Safety of Vitamin D Supplementation in Pediatric Patients with Obesity","Efecto De La Suplementación De Vitamina D En La Resistencia a La Insulina En Escolares Y Adolescentes Con Obesidad","VD","Inclusion Criteria:\n\n* Male and female participants.\n* Participants aged between 10 and 18 years.\n* Obesity as defined by a Body Mass Index (BMI) in the \\>95th percentile according to the World Health Organization's age and sex-specific tables.\n* Willingness to participate in the study.\n* Residency in Mexico City.\n\nExclusion Criteria:\n\n* Patients with comorbidities not attributable to obesity, such as chronic kidney disease, heart failure, liver cirrhosis, etc.\n* Patients with Prader-Willi syndrome, Albright's hereditary osteodystrophy, Borjesson-Forssman-Lehmann syndrome.\n* Patients currently taking vitamin supplements.\n* Patients undergoing pharmacological treatment for obesity.\n* Patients who already present insulin resistance and, although they have not previously received medication, are currently indicated for pharmacological treatment with metformin.","10 Years",{"count":231,"type":23},40,[26],"Introduction: Vitamin D deficiency is commonly observed in patients with obesity, primarily due to sequestration by adipose tissue. Recent research highlights the importance of this deficiency, showing a correlation between low vitamin D levels and mechanisms contributing to insulin resistance.\n\nObjectives: This study aims to compare the effects of supplementing with 4,000 IU of vitamin D versus 1,000 IU over six months on insulin resistance and the leptin\u002Fadiponectin ratio in school-aged children and adolescents with obesity.\n\nMaterials and Methods: A controlled clinical trial will be conducted involving 40 children with obesity aged 10 to 18 years (BMI \\>95th percentile). Participating children and their parents will undergo measurements such as weight, height, BMI, body fat, and Tanner stage. All participants will receive dietary and physical activity recommendations based on WHO guidelines. After initial assessments, participants will be randomly assigned to receive either 4,000 IU or 1,000 IU of vitamin D. They will be monitored monthly for capsule intake and adverse effects, with follow-up measurements of anthropometry, leptin, adiponectin, insulin \\& lipid profile.\n\nStatistical Analysis: Baseline characteristics will be compared using t-Student or U-Mann Whitney tests, depending on variable distribution. The intervention's impact will be assessed by calculating deltas for body fat and biochemical measurements, with significance tested using paired t-tests or Wilcoxon tests. Covariance analysis (ANCOVA) will be used to adjust for confounding variables.",[30,235,236],"Insulin Resistance","Obesity, Childhood",[34,238,33,239,240,241],"insulin resistence","leptin","adiponectin","pediatric","2025-03-21",{"date":244,"type":41},"2025-03-24",{"date":246,"type":41},"2025-03-01",{"date":248,"type":23},"2025-10-30",{"name":250,"class":251},"Coordinación de Investigación en Salud, Mexico","OTHER_GOV",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":18,"minAge":58,"maxAge":258,"enrollmentInfo":259,"targetDuration":4,"studyType":24,"phases":261,"briefSummary":262,"conditions":263,"keywords":269,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":276,"locationsCount":76},"100565457","effect-of-vitamin-d-supplementation-on-the-efficacy-and-adverse-effects-of-neoadjuvant-therapy-in-patients-with-breast-cancer-100565457","NCT06642428","Effect of Vitamin D Supplementation on the Efficacy and Adverse Effects of Neoadjuvant Therapy in Patients with Breast Cancer","Inclusion Criteria:\n\n1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination.\n3. Serum 25(OH)D levels less than 20 ng\u002Fml (50 nmol\u002FL).\n4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of 5.neoadjuvant chemotherapy or combined targeted therapy.\n\n6.Life expectancy of at least 6 months. 7.No other uncontrolled benign diseases at the time of recruitment. 8.All patients must have complete clinical medical records. 9.Willingness to voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of invasive breast cancer.\n2. Prior systemic treatment for the treatment or prevention of breast cancer.\n3. Known allergic reactions to vitamin D or calcium compounds.\n4. Comorbidities that may affect vitamin D or calcium balance or bone health.\n5. Vitamin D or calcium supplementation in the past 3 months.\n6. Presence of other tumors.\n7. Pregnant or lactating women.\n8. Individuals who do not wish to participate in the study.","80 Years",{"count":260,"type":23},140,[26],"This randomized controlled Phase III trial was designed to evaluate the impact of supplemental vitamin D (VD) on the efficacy and side effects of neoadjuvant therapy in patients with breast cancer.",[30,264,265,266,267,268],"Neoadjuvant Therapy","Breast Cancer","Adverse Reaction","Efficacy","Chemotherapy",[30,265,266,267],"2025-01-16",{"date":272,"type":41},"2025-01-17",{"date":274,"type":41},"2024-10-18",{"date":67,"type":23},{"name":277,"class":48},"Jiuda Zhao",{"id":279,"slug":280,"hasResults":11,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":18,"minAge":58,"maxAge":258,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":294,"locationsCount":76},"100565458","effect-of-vitamin-d-supplementation-on-chemotherapy-side-effects-after-adjuvant-chemotherapy-for-breast-cancer-100565458","NCT06642441","Effect of Vitamin D Supplementation on Chemotherapy Side Effects After Adjuvant Chemotherapy for Breast Cancer","Inclusion Criteria:\n\n1. Age between 18 and 80 years, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n2. Primary diagnosis of breast cancer confirmed by preoperative pathological examination.\n3. Serum 25(OH)D levels less than 20 ng\u002Fml (50 nmol\u002FL).\n4. Patients who have not previously received chemotherapy and who plan to undergo at least 4 cycles of\n5. Patients with adjuvant chemotherapy or combined targeted therapy.\n6. Life expectancy of at least 6 months.\n7. No other uncontrolled benign diseases at the time of recruitment.\n8. All patients must have complete clinical medical records.\n9. Willingness to voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n1. History of invasive breast cancer.\n2. Prior systemic treatment for the treatment or prevention of breast cancer.\n3. Known allergic reactions to vitamin D or calcium compounds.\n4. Comorbidities that may affect vitamin D or calcium balance or bone health.\n5. Vitamin D or calcium supplementation in the past 3 months.\n6. Presence of other tumors.\n7. Pregnant or lactating women.\n8. Individuals who do not wish to participate in the study.",{"count":285,"type":23},100,[26],"This randomized controlled Phase III trial was designed to evaluate the effect of vitamin D supplementation (VD) on chemotherapy side effects following adjuvant chemotherapy in breast cancer",[30,268,265,266],[30,265,266],{"date":272,"type":41},{"date":292,"type":41},"2024-12-01",{"date":67,"type":23},{"name":277,"class":48}]